cancer

Bristol Myers Squibb is nixing BeiGene's Abraxane deal in China amid manufacturing woes. Is their cancer rivalry really to blame?
Fierce Pharma
Thu, 10/14/21 - 11:09 am
cancer
Bristol Myers Squibbe
BeiGene
Abraxane
China
drug manufacturing
CRISPR touts new results as fresh questions surround 'off-the-shelf' CAR-T
BioPharma Dive
Tue, 10/12/21 - 11:40 pm
cancer
cell therapy
CRISPR Therapeutics
Merck’s Davis Looking to Diversify in Preparation for Keytruda Patent Cliff
BioSpace
Wed, 10/6/21 - 11:23 pm
Merck
Keytruda
patents
patent cliff
cancer
Rob Davis
Exo Therapeutics adds $78M as cancer, inflammation drugs march toward clinic
MedCity News
Tue, 10/5/21 - 09:38 pm
Exo Therapeutics
funding
cancer
exosites
Merck KGgA venture arm bets on ‘next generation’ cancer therapeutics player
Biopharma Reporter
Tue, 10/5/21 - 10:53 am
Merck KGaA
M Ventures
venture capital
iOmx Therapeutics
cancer
funding
Is the cancer immunotherapy market up for disruption as AstraZeneca, Regeneron-Sanofi, cheaper Chinese offerings line up?
Fierce Pharma
Sun, 10/3/21 - 08:27 pm
cancer
oncology
cancer immunotherapy
Merck
AstraZeneca
Regeneron
Sanofi
GSK's $4.2B bet on Merck KGaA's cancer drug goes up in smoke as pharmas cut ties after series of flops
Fierce Biotech
Thu, 09/30/21 - 10:58 pm
GSK
Merck KGaA
oncology
cancer
biliary tract cancer
Oncology the focus for big pharma catalysts
EP Vantage
Tue, 09/28/21 - 11:19 am
Big Pharma
cancer
oncology
Merck
Keytruda
AbbVie
Vraylar
Gilead Sciences
Trodelvy
Sanofi
Sarclisa
Novartis
ligelizumab
An In-Depth Look at Innovation on Cancer Research Day
BioSpace
Sun, 09/26/21 - 11:24 pm
cancer
oncology
R&D
Cue Biopharma
Celyad Oncology
Fore Biotherapeutics
X4 Pharmaceuticals
Elicio Therapeutics
OSE Immunotherapeutics
Sotio
GigaGen
Are Too Many Phase III Cancer Clinical Trials Set Up to Fail?
National Comprehensive Cancer Network
Sat, 09/25/21 - 10:57 pm
cancer
oncology
clinical trials
FDA's cancer drug advisors will review 2 more dangling accelerated approvals for multiple myeloma, leukemia
Endpoints
Thu, 09/23/21 - 10:34 pm
FDA
cancer
accelerated approvals
Secura Bio
Farydak
Multiple Myeloma
Acrotech Biopharma
Marqibo
Triumvira is Creating a Different Picture for Cancer Patients
BioSpace
Wed, 09/22/21 - 11:36 pm
Triumvira
CAR-T
cancer
solid tumors
San Diego Biotech Uncloaks with $60 Million to Tackle Treatment-Resistant Cancers
BioSpace
Tue, 09/21/21 - 10:51 pm
cancer
funding
San Diego
858 Therapeutics
How Inheret drives early detection for genetic cancers with its guidelines-based tool
MedCity News
Tue, 09/21/21 - 10:49 pm
Inheret
cancer
diagnostics
Boehringer Ingelheim acquires Abexxa Biologics
Biopharma Reporter
Tue, 09/21/21 - 10:56 am
Boehringer Ingelheim
M&A
Abexxa Biologics
cancer
antibodies
drug development
ESMO Preview: Highlights to Watch for This Year
BioSpace
Wed, 09/15/21 - 10:29 pm
ESMO
oncology
cancer
Gilead Sciences
Bristol Myers Squibb
Zymeworks
Amgen
Adaptimmune Therapeutics
TCR2 Therapeutics
Boehringer Ingelheim
Study: 1/3 of Cancer Accelerated Approval Indications Remain Despite Lack of Confirmation
BioSpace
Mon, 09/13/21 - 11:31 pm
FDA
accelerated approvals
cancer
oncology
Amgen's high-profile cancer med Lumakras set for rollout in England thanks to NHS access deal
Fierce Pharma
Sat, 09/11/21 - 10:18 pm
Amgen
Lumakras
UK
NHS
cancer
BioNTech reports promising data on mRNA cocktail in mouse models of colon cancer and melanoma
Fierce Biotech
Wed, 09/8/21 - 11:24 pm
BioNTech
cancer
colon cancer
melanoma
MRNA
Illumina and Merck Partner to ID Cancer Mutations
Medical Devices and Diagnostics Industry
Wed, 09/8/21 - 11:20 pm
Merck
Illumina
cancer
diagnostics
homologous recombination deficiency

Pages